Hematology Drugs Global Market Report 2018

1
Hematology Drugs Global Market Report 2018
Including Blood Products Anemia And Other Blood
Disorder Drugs Covering Novo Nordisk A/S, Shire
Plc, Bayer AG, Daiichi Sankyo Company, Limited,
Biogen Inc.
Feb 2018
2
Reasons to Purchase

• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high
  quality data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of
  order.
• Scope
• Markets Covered Blood Products Anemia And Other
  Blood Disorder Drugs
• Companies Mentioned Novo Nordisk A/S, Shire Plc,
  Bayer AG, Daiichi Sankyo Company, Limited,
  Biogen Inc.
• Countries Brazil, China, France, Germany, India,
  Italy, Japan, Spain, Russia, UK, USA and
  Australia.
• Regions Asia-Pacific, Western Europe, Eastern
  Europe, North America, South America, Middle
  East And Africa
• Time series Five years historic and forecast.

3
Hematology Drugs Market Characteristics
Hematology drugs market offers drugs, blood and
blood products that are used for the treatment
of diseases such as rare genetic disorders,
anemia, and conditions related to sickle cell
disease and other related diseases. Some of the
major hematology drugs include Albumin, Epoetin,
Zoladex, and Hyskon. The market numbers within
this briefing are restricted to pharmaceutical
(drug) treatments and do not cover biologic
treatments for these conditions which are
included in a separate briefing. The hematology
drugs industry is further classified as follows
Blood Products companies produce blood
components such as Anemia And Other Blood
Disorder Drugs companies produce drugs that can
be used to In this report market value is
defined as the revenues organizations earn by
selling their goods and services within the
specified market, based on the price at which
they sell. Only goods and services traded between
entities are included. The revenues for a
specified geography are consumption values that
is, they are revenues generated by organizations
in the specified geography within the specified
market, irrespective of where they are produced.
4
Hematology Drugs Market Historic Growth
The global hematology drugs market grew from X
billion in 2013 to X billion in 2017 at a
compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global hematology drugs market
during 2013 2017.
Drivers of the Market Restraints on the Market
5
Hematology Drugs Market Forecast Growth
The global hematology drugs market is expected to
grow from XX billion in 2017 to 50.8 billion
in 2021 at a compound annual growth rate (CAGR)
of XX. Going forward, unhealthy lifestyle
leading to anemia and coagulation disorders,
along with increased longevity and the launch of
pipeline drugs is set to drive the market for
hematology drugs. The chart and table below
shows the year-on-year growth of the global
hematology drugs market during 2017 - 2021.
Drivers of the Market Restraints on the Market
6
Hematology Drugs Market Segmentation
The chart and table below shows the split of the
hematology drugs market in 2017.
The total market value for hematology drugs was
X billion in 2017. The markets that are covered
include Blood Products Anemia And Other Blood
Disorder Drugs. Blood Products was the X largest
segment in the hematology drugs market with X
share of the market. The market value for the
blood products was X billion in 2017. Anemia
And Other Blood Disorder Drugs made up around X
share of the market. The market value for the
anemia and other blood disorder drugs was X
billion in 2017.
7
Hematology Drugs Market Regional And Country
Analysis
The Asia Pacific was the largest region in the
hematology drugs market in 2017, hematology
drugs for X billion or X market share. North
America was the x largest region hematology drugs
for X billion or X market share. Western
Europe was the x largest region hematology drugs
for X billion or X market share.
8
Hematology Drugs Market Competitive Landscape
The leading competitors in the global hematology
drugs market are Novo Nordisk A/S, Shire Plc,
Bayer AG, Daiichi Sankyo Company Limited, Biogen
Inc. The chart and table below displays the
percentage market share of the top players in
the hematology drugs market industry.
Novo Nordisk A/S generated revenues of XX
billion for the financial year 2016, an XX
increase from the previous year. Shire Plc.
generated revenues of XX billion for the
financial year 2016. Bayer AG generated revenues
of XX billion for the financial year 2016, an
XX increase from the previous year. Daiichi
Sankyo Company, Limited generated revenues of XX
billion for the financial year 2016, an XX
decrease from the previous year.
9
Biogen Inc. generated revenues of XX billion for
the financial year 2016, an XX increase from
the previous year. Pfizer Inc. generated revenues
of XX billion for the financial year 2016, an
XX increase from the previous year. Company
Profile Novo Nordisk A/S Overview Novo Nordisk
was the largest company in the hematology drug
market with a XX share of the market in 2017.
The company was founded in 1925 and is
headquartered in Bagsvaerd, Denmark. It is a
healthcare company involved in discovering,
developing, manufacturing, and marketing of
pharmaceutical products. Novo Nordisk markets
and distributes its products through
distributors and independent agents
worldwide. Products and Services Novo Nordisk
operates through following divisions The
Diabetes And Obesity Care division offers
insulin The Biopharmaceuticals division offers
products related to Strategy Novo Nordisks
growth strategy is to expand its hematology
business by developing new drugs for treatment
of hematologic disorders. In June 2017, the Food
and Drug Administration of the US approved Novo
Nordisks Rebinyn coagulation treatment for the
treatment of hemophilia B. Rebinyn, which can be
used for treatment and control of bleeding
disorders in patients with
Financial Performance Novo Nordisks
Biopharmaceuticals
Haemophilia division,
and Norditropin sections in its
are involved in hematology drug
10
manufacturing, and generated revenues of DKK XX
billion (XX billion) for the financial year
2016, a XX increase from the previous
year. Shire Plc Overview Products and Services
Strategy Financial Performance Bayer
AG Overview Products and Services
Strategy Financial Performance Daiichi Sankyo
Company Limited Overview Products and Services
Strategy Financial Performance Biogen
Inc. Overview Products and Services
Strategy Financial Performance